Endocrine Resistance in Breast Cancer: Molecular Pathways and Rational Development of Targeted Therapies
Authors:
- 12 March 2012
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 8 (3) , 273-292
Abstract
Endocrine resistance presents a major challenge in the management of estrogen receptor (ER)-positive breast cancer and is an area under intense investigation. Although the underlying mechanism is still poorly understood, many studies point towards the 'cross-talk' between ER and growth factor receptor signaling pathways as the key in the development of estrogen-independent growth in breast cancer. This review aims to provide the reader our current understanding of various molecular pathways that mediate endocrine resistance and that are being evaluated as therapeutic targets for ER-positive breast cancer. While most of the agents that target these pathways have only been tested in Phase I or small Phase II trials, some have shown encouraging results. A critical issue that remains is the development of research strategies and clinical trials that take into account the molecular heterogeneity of ER-positive breast cancer.Keywords
This publication has 175 references indexed in Scilit:
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Significance of ER–Src axis in hormonal therapy resistanceBreast Cancer Research and Treatment, 2010
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other failBiochemical Pharmacology, 2010
- Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment ResponseJournal of Mammary Gland Biology and Neoplasia, 2010
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 2009
- IGF-1 Receptor Inhibitors in Clinical Trials—Early LessonsJournal of Mammary Gland Biology and Neoplasia, 2008
- Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrantBreast Cancer Research and Treatment, 2008
- Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007